ClinicalTrials.gg
RecruitingNCT06522594Updated Jul 26, 2024

REMAP ECMO - Beta Receptor Modulation Trial

A Phase 2 interventional study of Esmolol in Heart Failure and Cardiogenic Shock, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Erasmus Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.

Planned enrollment
214th of 234
20 · median 284
Started
2024
with 19 others
Phase 2
43 of 313
3 open now
Primary completion
2025-12
later than 14 of 79 live
Registered
276th of 313
by date
Lead sponsor
9 of 313
Erasmus Medical Center

Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 214th largest by planned enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2024, is one of 43 in phase 2, reaches primary completion later than 14 of the 79 other live ones, and was the 276th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Heart Failure with a site in Netherlands, or all of them as a file.
02

Study summary

In this phase 2, single center, randomized clinical pilot trial, investigators will study the effect of a strategy involving a reduction of beta receptor (BR) stimulation (by decreasing dobutamine dosages) and subsequent BR inhibition (through ultra-short acting betablockers), versus a (routine) strategy with continued BR stimulation through dobutamine infusion, on heart rate in patients with cardiogenic shock due to left- or bi-ventricular failure being supported by V-A ECMO.

Read the detailed description

Despite the great benefits of Venoarterial ExtraCorporeal Membrane Oxygenation (V-A ECMO) and its rapidly increasing usage, even today, 30 till 70 percent of patients cannot be weaned from ECMO support and up to 50 percent of patients will eventually die in the first year. These high incidences of mortality and failure to wean from V-A ECMO support seem largely attributable to failure of the heart to recover in the context of inotropic drug administration and high sympathetic drive due to severe illness (further stressing an already failing heart). As V-A ECMO support creates a "safety window" where organ perfusion no longer relies on native cardiac output, therapeutic focus could be shifted to cardioprotective treatments. Cardioprotective treatments typically include beta blockers (BB) which have unequivocally shown benefits on mortality and morbidity in other patient categories with heart failure with reduced ejection fraction (HFrEF).

The investigators hypothesize that, in selected patients with cardiogenic shock undergoing V-A ECMO support, application of BBs is feasible and safe, and can effectively reduce heart rate.

03

Conditions studied

  • Heart Failure
  • Cardiogenic Shock

Keywords

  • Veno-Arterial ExtraCorporeal Membrane Oxygenation
  • Betablocker
  • Esmolol
  • Cardiogenic shock
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years,
  • Having received V-A ECMO support for severe circulatory insufficiency due to left- or bi-ventricular failure.
  • ≤ 16 hours after initiation of V-A ECMO support
  • Receiving ≥ 2 mcg/kg/min of dobutamine.
  • Norepinephrine infusion ≤ 0.4 mcg/kg/min
  • Heart rate ≥ 80 bpm (being sinus rhythm, atrial fibrillation or atrial flutter) after V-A ECMO initiation

Exclusion criteria

Exclusion Criteria:

  • Objection during the deferred consent procedure
  • V-A ECMO usage confined to the period during surgery or another intervention (the ECMO was removed at the end of the intervention).
  • Concomitant durable Left Ventricular Assist Device (LVAD)
  • Polymorphic ventricular tachycardia necessitating BB therapy
  • Isolated right ventricular failure (e.g. due to pulmonary embolism)
  • Need of high dose dobutamine > 6.0 mcg/kg/min
  • Epinephrine infusion
  • Signs of insufficient trans cardiac flow:

    • Absence of aortic valve opening
    • Pulse pressure \<10 mmHg (with intra-aortic balloon pump (IABP) standby)
    • Spontaneous contrast in the heart at echocardiography
  • for-, intolerance to- or allergy to esmolol
  • Second- or third- degree AV block
  • Pregnancy
  • of less than 24 hours
  • Participation in another randomized clinical trial (e.g. On Scene trial or Left Ventricular unloading trial)
  • Inability to start study treatment within 4 hours after randomization
  • Post heart transplantation patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Beta receptor inhibition arm

    In the "beta receptor (BR) inhibition arm", patients are randomized to a biphasic strategy where BR stimulation is phased out and esmolol (BR blockade) is initiated in a sequential way. During a first phase, milrinone (a phosphodiesterase inhibitor which is routinely used in V-A ECMO supported patients) infusion will be initiated (if not already being given) at 0.25 mcg/kg/min and dobutamine dosages will be decreased every hour and eventually stopped according to the following sequence; 6 - 4 - 2 - 1 - 0 mcg/kg/min. In a second phase, esmolol is initiated with a dosage of 25 mcg/kg/min. The dose of the BB will be increased with increments of 25 mcg/kg/min every hour until reaching a heart rate between 50 and 70 bpm or a maximum dose of 200 mcg/kg/min. Prior to each dosage escalation, a reassessment of the hemodynamic situation will be done. The BR inhibition strategy will be continued until 48 hours after randomization or earlier when deemed necessary by the treating physician.

    Drug: Esmolol

  • No intervention
    Routine care arm

    The dosage of dobutamine infusion is at the discretion of the treating physician but is typically continued until 48 hours after randomization. All other medication will be managed according to the needs of the patient at the discretion of the treating physician.

Interventions

  • A vey cardioselective, short-acting betablocker, with an ultra-short half life time.

06

What researchers measure

Primary outcomes

  1. Change (delta) in heart rate 24 hours after randomization.

    The average heart rate on basis of all observations during 5 minutes at both time points (t=0 and t=24h).

    Time frame: 24 hours after randomization

Secondary outcomes

  1. Percentage of patients having received esmolol

    Time frame: after 48 hours

  2. Vasopressor score

    using the calculation as described in literature, excluding inotropic medication

    Time frame: at baseline, 24 and 48 hours

  3. Occurrence of new onset ventricular and/or atrial arrhythmias after randomization

    Time frame: during the first 48 hours

  4. Left ventricular outflow tract velocity time integral (LVOT VTI)

    Echocardiography parameters

    Time frame: at baseline, 24 and 48 hours

  5. Cardiac output

    Pulmonary arterial catheter parameter

    Time frame: at baseline, 24 and 48 hours

  6. Stroke volume index

    Pulmonary arterial catheter parameter

    Time frame: at baseline, 24 and 48 hours

  7. Pulmonary capillary wedge pressure

    Pulmonary arterial catheter parameter

    Time frame: at baseline, 24 and 48 hours

  8. Central venous pressure

    Pulmonary arterial catheter parameter

    Time frame: at baseline, 24 and 48 hours

  9. Mixed venous oxygen saturation (SvO2)

    Pulmonary arterial catheter parameter

    Time frame: at baseline, 24 and 48 hours

  10. Lactate level

    Time frame: at baseline, 24 and 48 hours

  11. Troponin

    measured at baseline, 24- and 48- hours after randomization, and Area Under the Curve (AUC)

    Time frame: At 24 and 48 hours after randomization

  12. Myocardial oxygen consumption

    Estimated by calculating the pressure volume (PV) area on basis of non-invasive PV loop assessments using echocardiography and pulmonary artery catheter measurements

    Time frame: At 24 and 48 hours after randomization

  13. Plasma NT-proBNP levels

    Biomarker for cardiac stretch

    Time frame: At baseline and 48 hours after randomization

  14. Plasma Creatine Kinase MB levels

    Biomarker for cardiac injury

    Time frame: At baseline and 48 hours after randomization

  15. FiO2 suppletion

    Time frame: At 24 and 48 hours after randomization

  16. Plasma metanephrine levels

    Time frame: At baseline and 24 after randomization

  17. Plasma normetanephrines levels

    Time frame: At baseline and 24 after randomization

  18. Maximum median dosages of esmolol

    Time frame: after 48 hours

  19. Ejection fraction (EF)

    Echocardiography parameters

    Time frame: at baseline, 24 and 48 hours

  20. Tricuspid annular plane systolic excursion (TAPSE).

    Echocardiography parameters

    Time frame: at baseline, 24 and 48 hours

  21. Positive End Expiratory Pressure (PEEP) level

    Time frame: At 24 and 48 hours after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Meuwese CL, Hermens JA, de Haan M, Braithwaite SA, Ramjankhan F, Buijsrogge MP, de Jonge N, Kirkels JH, de Jong M, Pasma W, Vromen-Wijsman JLP, Kraaijeveld AO, de Waal EE, Torn E, Platenkamp M, van der Heijden JJ, Cremer OL, van Dijk D, Donker DW. Twelve years of circulatory extracorporeal life support at the University Medical Centre Utrecht. Neth Heart J. 2021 Jul;29(7-8):394-401. doi: 10.1007/s12471-021-01552-z. Epub 2021 Mar 6. PubMed 33675521 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. Erratum In: Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670. PubMed 34447992 ↗
  • Flather MD, Gollop ND. Understanding Mechanisms of Action of Beta-Blockers in Heart Failure With Reduced and Preserved Ejection Fraction. JACC Heart Fail. 2016 Feb;4(2):150-151. doi: 10.1016/j.jchf.2015.12.009. No abstract available. PubMed 26823116 ↗
  • Rahhal A, Omar AS, Aljundi A, Kasem M, Mahfouz A, Alyafei S. Successful Use of Intravenous B-blocker Therapy in Cardiogenic Shock Supported With Venoarterial Extracorporeal Membrane Oxygenation: A Case Series. Curr Probl Cardiol. 2022 Nov;47(11):101071. doi: 10.1016/j.cpcardiol.2021.101071. Epub 2021 Nov 26. PubMed 34838902 ↗
  • Brugts JJ, Manintveld O, Constantinescu A, Donker DW, van Thiel RJ, Nieman K, Jewbali LS, Zijlstra F, Caliskan K. Preventing LVAD implantation by early short-term mechanical support and prolonged inodilator therapy : A case series with acute refractory cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation and optimised medical strategy. Neth Heart J. 2014 Apr;22(4):176-81. doi: 10.1007/s12471-013-0509-5. PubMed 24424723 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 18 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 26, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 3, 2025
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06522594
Responsible party
Christiaan Meuwese (Cardiologist-Intensivist, Erasmus Medical Center) — Principal investigator
First posted
Jul 26, 2024
Start date
Jun 1, 2024
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 3, 2025 (estimated)
Last update
Jul 26, 2024

Study contacts

Christiaan L. Meuwese, MD, PhD
Contact
c.meuwese@erasmusmc.nl
0631135752
Myrthe PJ van Steenwijk, MD
Contact
m.p.j.vansteenwijk@erasmusmc.nl
0650162551
Christiaan L. Meuwese
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esmolol

Start the discussion